What question did this study set out to answer?

To evaluate the current management strategies for locally advanced esophageal and EGJ cancers and highlight emerging trends.

November 8, 2025CancersOpen Access

Current Management of Locally Advanced Esophageal and Esophagogastric Junction Cancers: Clinical Evidence and Evolving Strategies

View Full Paper

Ask AI

Bookmark

Authors

Review reveals immunotherapy improves outcomes in adenocarcinoma, suggesting personalized strategies for better management.

To evaluate the current management strategies for locally advanced esophageal and EGJ cancers and highlight emerging trends.
Comprehensive overview of clinical evidence regarding chemoradiotherapy, surgery, and immunotherapy
Analysis of treatment sequencing and patient selection
Evaluation of biomarkers like microsatellite instability-high
Discussion of non-operative management options in select cases.
Standard treatment includes chemotherapy, chemoradiotherapy, and surgery based on cancer type.
Immunotherapy has shown promise in improving surrogate endpoints for adenocarcinoma.
Personalization strategies are critical due to ongoing challenges with treatment outcomes.

Donato et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark